19 June 2012 - Full Spectrum Genetics Inc, a privately held protein analysis and engineering platform and product company, has announced today that it has entered into a strategic collaboration with an undisclosed global pharmaceutical company.

The collaboration is aimed at generating multiple novel therapeutic protein and antibody product candidates.

According to the terms of the contract, Full Spectrum Genetics will be responsible for engineering and analysing versions of specified molecules, using its MapEng(tm) platform.